MICHAEL SCOTT SABEL

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor
    Michael S Sabel
    University of Michigan, Department of Surgery, Division of Surgical Oncology, 3304 Cancer Center, 1500 East Medical Center, Ann Arbor, MI 48109 0932, USA
    Cryobiology 53:360-6. 2006
  2. ncbi Is duct excision still necessary for all cases of suspicious nipple discharge?
    Michael S Sabel
    Departments of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Breast J 18:157-62. 2012
  3. ncbi Patterns of Internet use and impact on patients with melanoma
    Michael S Sabel
    Department of Surgery, University of Michigan Medical School and Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    J Am Acad Dermatol 52:779-85. 2005
  4. ncbi The role of the surgeon in the management of melanoma
    M S Sabel
    Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, 48109, USA
    Minerva Chir 61:141-54. 2006
  5. ncbi Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer
    Michael S Sabel
    Division of Surgical Oncology, University of Michigan, Ann Arbor, MI, USA
    Breast Cancer Res Treat 122:325-36. 2010
  6. ncbi Locoregional therapy of breast cancer: maximizing control, minimizing morbidity
    Michael S Sabel
    University of Michigan Comprehensive Cancer Center, 3304 Cancer Center, Division of Surgical Oncology, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Expert Rev Anticancer Ther 6:1281-99. 2006
  7. ncbi Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells
    Michael S Sabel
    Division of Surgical Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Surgery 142:749-60. 2007
  8. ncbi Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres
    Michael S Sabel
    Division of Surgical Oncology, University of Michigan, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0932, USA
    J Immunother 30:808-16. 2007
  9. ncbi Sarcopenia as a prognostic factor among patients with stage III melanoma
    Michael S Sabel
    Department of Surgery, University of Michigan, Ann Arbor, MI, USA
    Ann Surg Oncol 18:3579-85. 2011
  10. ncbi Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses
    Michael S Sabel
    Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Department of Surgery, 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Cryobiology 58:1-11. 2009

Research Grants

Detail Information

Publications66

  1. ncbi Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor
    Michael S Sabel
    University of Michigan, Department of Surgery, Division of Surgical Oncology, 3304 Cancer Center, 1500 East Medical Center, Ann Arbor, MI 48109 0932, USA
    Cryobiology 53:360-6. 2006
    ..Cryoablation prior to surgical resection of breast cancer can be used as a method to generate effector T-cells for adjuvant adoptive cellular immunotherapy...
  2. ncbi Is duct excision still necessary for all cases of suspicious nipple discharge?
    Michael S Sabel
    Departments of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Breast J 18:157-62. 2012
    ..In selected patients with suspicious nipple discharge, but normal physical exam and diagnostic imaging, short-term observation with repeat evaluation seems reasonable for patients who do not desire duct excision...
  3. ncbi Patterns of Internet use and impact on patients with melanoma
    Michael S Sabel
    Department of Surgery, University of Michigan Medical School and Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    J Am Acad Dermatol 52:779-85. 2005
    ..Our objective was to examine the use of the Internet and its impact among patients with melanoma...
  4. ncbi The role of the surgeon in the management of melanoma
    M S Sabel
    Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, 48109, USA
    Minerva Chir 61:141-54. 2006
    ..This article will review the evolution of melanoma surgery and the evidence behind today's recommendations...
  5. ncbi Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer
    Michael S Sabel
    Division of Surgical Oncology, University of Michigan, Ann Arbor, MI, USA
    Breast Cancer Res Treat 122:325-36. 2010
    ..The addition of IL-18 did not improve the efficacy...
  6. ncbi Locoregional therapy of breast cancer: maximizing control, minimizing morbidity
    Michael S Sabel
    University of Michigan Comprehensive Cancer Center, 3304 Cancer Center, Division of Surgical Oncology, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Expert Rev Anticancer Ther 6:1281-99. 2006
    ..This article will review the importance of attaining optimum local control with minimum morbidity and examine where the future of locoregional therapy of breast cancer may lie...
  7. ncbi Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells
    Michael S Sabel
    Division of Surgical Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Surgery 142:749-60. 2007
    ..The local and sustained release of IL-12 and TNF-alpha using PLAM synergistically activate both a cytotoxic T-cell and NK cell response, although their impact varies with MHC class I expression...
  8. ncbi Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres
    Michael S Sabel
    Division of Surgical Oncology, University of Michigan, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0932, USA
    J Immunother 30:808-16. 2007
    ....
  9. ncbi Sarcopenia as a prognostic factor among patients with stage III melanoma
    Michael S Sabel
    Department of Surgery, University of Michigan, Ann Arbor, MI, USA
    Ann Surg Oncol 18:3579-85. 2011
    ..If the latter were true, then biologic frailty, and not age, should be an independent prognostic factor in melanoma...
  10. ncbi Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses
    Michael S Sabel
    Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Department of Surgery, 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Cryobiology 58:1-11. 2009
    ..This article reviews the existing evidence regarding tumor cryo-immunology and puts forward hypotheses regarding patient, tumor and technical factors that may influence the resultant immune response and warrant further investigation...
  11. ncbi Residual disease after re-excision lumpectomy for close margins
    Michael S Sabel
    Division of Surgical Oncology, Department of Surgery, Biostatistics Core of the University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Surg Oncol 99:99-103. 2009
    ..We sought to examine the incidence of residual disease after re-excision for close margins and to identify predictive factors that may better select patients for re-excision...
  12. ncbi Point: Interferon-alpha for adjuvant therapy for melanoma patients
    Michael S Sabel
    Department of Surgery, University of Michigan Comprehensive Cancer Center, 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    J Natl Compr Canc Netw 2:61-8. 2004
    ..Informed patients who have elected to forego interferon and patients with lower risk lesions can be offered participation in clinical trials with a no-treatment control arm...
  13. ncbi Rate of freeze alters the immunologic response after cryoablation of breast cancer
    Michael S Sabel
    Division of Surgical Oncology, University of Michigan, Ann Arbor, MI, USA
    Ann Surg Oncol 17:1187-93. 2010
    ..We sought to examine the impact that variances in technique might have on the immune response and examine the mechanism by which cryoablation may stimulate an antitumor immune response...
  14. ncbi Sentinel lymph node biopsy before or after neoadjuvant chemotherapy: pros and cons
    Michael S Sabel
    Department of Surgery, University of Michigan Comprehensive Cancer Center, 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Surg Oncol Clin N Am 19:519-38. 2010
    ..This article addresses the clinical questions regarding the 2 approaches including the accuracy of the procedure and the prognostic information gleaned...
  15. ncbi Surgical considerations in early-stage breast cancer: lessons learned and future directions
    Michael S Sabel
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Semin Radiat Oncol 21:10-9. 2011
    ..and intraoperative margin analysis. This article reviews several areas in which the surgeon can help ensure the success of breast-conservation therapy...
  16. ncbi Validation of statistical predictive models meant to select melanoma patients for sentinel lymph node biopsy
    Michael S Sabel
    Department of Surgery, University of Michigan Health System, 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI, 48109 0932, USA
    Ann Surg Oncol 19:287-93. 2012
    ..We sought to validate recently published models meant to predict sentinel node status...
  17. ncbi CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice
    Michael S Sabel
    Department of Surgery, 3304 Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Cancer Immunol Immunother 54:944-52. 2005
    ..These results sustain the notion that human anti-tumor immune response can be augmented (in vivo) by blocking the interaction between CTLA-4 and B7...
  18. ncbi Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity
    Michael S Sabel
    Division of Surgical Oncology, University of Michigan, Ann Arbor, Michigan, USA
    Ann Surg Oncol 11:147-56. 2004
    ....
  19. ncbi Pros and cons of adjuvant interferon in the treatment of melanoma
    Michael S Sabel
    University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
    Oncologist 8:451-8. 2003
    ..This manuscript reviews the leading arguments for and against its routine use and addresses questions regarding its role in the management of high-risk malignant melanoma...
  20. ncbi Immunologic approaches to breast cancer treatment
    Michael S Sabel
    Department of Surgery, University of Michigan, 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Surg Oncol Clin N Am 14:1-31, v. 2005
    ..Obstacles to the clinical effectiveness of immunotherapies in breast cancer are also discussed...
  21. ncbi Immunologic response to cryoablation of breast cancer
    Michael S Sabel
    University of Michigan, 3304 Cancer Center, East Medical Center, 1500 East Medical Center, Ann Arbor, MI 48109 0932, USA
    Breast Cancer Res Treat 90:97-104. 2005
    ..To help define the mechanisms involved in the cryoimmunologic response, we compared cryosurgery to surgery in a murine model of breast cancer...
  22. ncbi Cryoablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial
    Michael S Sabel
    Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Ann Surg Oncol 11:542-9. 2004
    ..We conducted a multi-institutional pilot safety study of cryoablation in the treatment of primary breast carcinomas...
  23. ncbi Sentinel node biopsy prior to neoadjuvant chemotherapy
    Michael S Sabel
    Breast Oncology Program and Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Am J Surg 186:102-5. 2003
    ..Sentinel lymph node biopsy prior to induction chemotherapy may address both...
  24. ncbi Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma?
    Michael S Sabel
    University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
    Drugs 63:1053-8. 2003
    ..This article reviews the existing data and attempt to address the arguments for and against a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma...
  25. ncbi Tumor vaccines: a role in preventing recurrence in melanoma?
    Michael S Sabel
    University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    Am J Clin Dermatol 3:609-16. 2002
    ....
  26. ncbi Mastectomy and concomitant sentinel lymph node biopsy for invasive breast cancer
    Michael S Sabel
    Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, 3304 Cancer Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109, USA
    Am J Surg 187:673-8. 2004
    ..Although sentinel lymph node biopsy (SNLB) has become a standard ancillary to breast conservation, there remains a hesitancy to perform SLNB concomitant with mastectomy primarily because of concerns regarding reoperation for a positive SLN...
  27. ncbi Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease
    Hank C Hill
    Department of Surgery, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 62:7254-63. 2002
    ..These results establish that neoadjuvant in situ tumor immunotherapy with IL-12 + GM-CSF microspheres induces both innate and adaptive antitumor immune responses resulting in the eradication of disseminated disease...
  28. ncbi Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity
    Alisha Arora
    Division of Surgical Oncology, University of Michigan, Ann Arbor, Michigan 48109-0932, USA
    J Surg Oncol 94:403-12. 2006
    ..Neoadjuvant treatment was significantly superior to postoperative autologous cellular vaccines using IL-12 and TNF-alpha PLAM...
  29. ncbi Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation
    Erika A Newman
    Department of Surgery, The University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Ann Surg Oncol 14:2946-52. 2007
    ..We report findings using a novel comprehensive approach to axillary management of node-positive-patients receiving neoadjuvant chemotherapy...
  30. ncbi Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence
    Kandice E Kilbride
    Department of Surgical Oncology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Ann Surg Oncol 15:3252-8. 2008
    ..The value of axillary staging prior to delivery of neoadjuvant chemotherapy (NEO) for breast cancer is controversial. Our goal was to analyze the prognostic and therapeutic impact of axillary staging on recurrence...
  31. ncbi Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node
    Aeisha K Rivers
    Department of Surgery, St. Joseph's Hospital and Medical Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, USA
    Ann Surg Oncol 13:36-44. 2006
    ..Patients with larger primary tumors, lymphovascular invasion, and extranodal extension are more likely to have ALND findings that will affect their cancer management...
  32. ncbi Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study
    Sandra L Wong
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 13:809-16. 2006
    ..CONCLUSIONS: This study underscores the importance of ongoing prospective randomized trials in determining the therapeutic value of CLND after positive SLN biopsy in melanoma patients...
  33. ncbi Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients
    Amy C Degnim
    Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA
    Cancer 98:2307-15. 2003
    ....
  34. ncbi Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis
    Rohit Mehra
    Department of Pathology, University of Michigan Medical School, Ann Arbor, 48109, USA
    Cancer Res 65:11259-64. 2005
    ..Our data suggest that immunohistochemical analysis of GATA3 may be the basis for a new clinically applicable test to predict tumor recurrence early in the progression of breast cancer...
  35. ncbi Translational research in melanoma
    Susan Tsai
    University of Michigan Comprehensive Cancer Center, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Surg Oncol Clin N Am 17:391-419, ix-x. 2008
    ..With this in mind, there has been a fervent attempt to identify novel approaches to melanoma therapy and translate them into clinical use...
  36. ncbi Melanoma: adjuvant therapy and other treatment options
    Alicia Terando
    University of Michigan Comprehensive Cancer Center, 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Curr Treat Options Oncol 4:187-99. 2003
    ....
  37. ncbi The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma
    Sandra C Paek
    Department of Dermatology, University of Michigan Health System, Ann Arbor, Michigan, USA
    Cancer 109:100-8. 2007
    ..The objectives of the current study were to verify those previous results and to create a prediction model for the better selection of which patients with melanoma should undergo SLN biopsy...
  38. ncbi Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?
    Timothy L Frankel
    Department of Surgery, University of Michigan Health System, Ann Arbor, MI, USA
    Ann Surg Oncol 15:2403-11. 2008
    ..We examined whether the size and location of the metastases within the SLN may help further stratify the risk of additional positive NSLN...
  39. ncbi Obesity and angiolymphatic invasion in primary breast cancer
    Erin F Gillespie
    University of Michigan Medical School, Ann Arbor, MI, USA
    Ann Surg Oncol 17:752-9. 2010
    ....
  40. ncbi Lymphatic mapping and sentinel lymph node biopsy for patients with local recurrence after breast-conservation therapy
    Erika A Newman
    Department of Surgery, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, USA
    Ann Surg Oncol 13:52-7. 2006
    ..001). CONCLUSIONS: Lymphatic mapping is feasible in patients undergoing mastectomy for LR and is likely to identify aberrantly located sentinel lymph nodes that would otherwise be overlooked with a conventional completion mastectomy...
  41. ncbi Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma
    Michael S Sabel
    Department of Surgery, University of Michigan Health System, Ann Arbor, MI 48109-0932, USA
    J Am Coll Surg 201:37-47. 2005
    ..Serial sectioning and immunohistochemistry on the NSLN in any "low-risk" group must be performed in a clinical trial to confirm that residual disease is unlikely before avoiding CLND can be recommended...
  42. ncbi Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy
    Amina Khan
    Department of Surgery, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, USA
    Ann Surg Oncol 12:697-704. 2005
    ....
  43. ncbi What is a sentinel node? Re-evaluating the 10% rule for sentinel lymph node biopsy in melanoma
    Hidde M Kroon
    Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48105, USA
    J Surg Oncol 95:623-8. 2007
    ..However, this increases the number of SLN removed and the time and cost of the procedure. We examined the impact of raising this threshold on the accuracy of the procedure...
  44. ncbi Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram
    Amy C Degnim
    Department of Surgery, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    Am J Surg 190:543-50. 2005
    ..The accurate prediction of nonsentinel node (NSN) metastasis in breast cancer patients remains uncertain...
  45. ncbi Wide excision without radiation for desmoplastic melanoma
    Alisha Arora
    Department of Surgery, University of Michigan, Ann Arbor, Michigan 48105, USA
    Cancer 104:1462-7. 2005
    ..This finding suggests that, for patients with desmoplastic melanoma, wide local excision with careful attention to appropriate margins produces excellent local control rates without the need for adjuvant radiation...
  46. ncbi Is blue dye indicated for sentinel lymph node biopsy in breast cancer patients with a positive lymphoscintigram?
    Amy C Degnim
    Division of Surgical Oncology, University of Michigan Health System, 1500 E Medical Center Drive, 3308 CGC Box 0932, Ann Arbor, Michigan, 48109, USA
    Ann Surg Oncol 12:712-7. 2005
    ..We hypothesized that blue dye could be safely omitted in the subgroup of patients who have evidence of successful sentinel node localization by lymphoscintigraphy...
  47. ncbi RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast
    Celina G Kleer
    Department of Pathology and Internal Medicine, University of Michigan, Ann Arbour, MI 48109 0054, USA
    Breast Cancer Res Treat 93:101-10. 2005
    ..We hypothesized that RhoC expression would identify aggressive, non-IBC tumors breast cancer patients at any stage with worse outcomes defined as recurrence and/or metastasis...
  48. ncbi Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma
    Amir A Ghaferi
    Department of Surgery, University of Michigan Health System, Ann Arbor, MI, USA
    Ann Surg Oncol 16:2978-84. 2009
    ..There may be additional prognostic significance to melanoma spreading from the SLN to nonsentinel lymph nodes (NSLN). We examined the implications of a positive NSLN for overall and distant disease-free survival...
  49. ncbi Review of evidence-based support for pretreatment imaging in melanoma
    Michael S Sabel
    University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
    J Natl Compr Canc Netw 7:281-9. 2009
    ..This article reviews available literature on the role of pretreatment imaging in patients with newly diagnosed cutaneous melanoma...
  50. ncbi Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy
    Quintin Pan
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Health System, Ann Arbor, Michigan 48109, USA
    Cancer Res 65:8366-71. 2005
    ..Taken together, these results revealed that PKC epsilon plays a critical and causative role in promoting an aggressive metastatic breast cancer phenotype and as a target for anticancer therapy...
  51. ncbi Small (< 2.0-cm) breast cancers: mammographic and US findings at US-guided cryoablation--initial experience
    Marilyn A Roubidoux
    Department of Radiology, University of Michigan Comprehensive Cancer Center, 1500 E Medical Center Drive, Room 2910H, Ann Arbor, MI 48109-0326, USA
    Radiology 233:857-67. 2004
    ..Tumor size, mammographic density, and US characteristics may be indicators of likelihood of complete cryoablation...
  52. ncbi EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
    Celina G Kleer
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:11606-11. 2003
    ..This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation...
  53. ncbi Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model
    Vernon K Sondak
    Department of Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
    Ann Surg Oncol 11:247-58. 2004
    ..Several factors have been variably, and sometimes discordantly, reported to have predictive value for SLN metastasis to best select which patients require SLN biopsy...
  54. ncbi The role of sentinel lymph node biopsy for melanoma: evidence assessment
    Timothy M Johnson
    Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    J Am Acad Dermatol 54:19-27. 2006
  55. ncbi Efficacy of sentinel lymph node biopsy in male breast cancer
    Vincent M Cimmino
    Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0932, USA
    J Surg Oncol 86:74-7. 2004
    ..SLNB has been championed as a procedure aimed at preventing those morbidities. We recently have evaluated the role of SLNB in the treatment of men with early stage breast cancer...
  56. ncbi Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy
    Michael S Sabel
    Division of Surgical Oncology, Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
    Surgery 141:728-35. 2007
    ..We sought to examine the effect this change has on the morbidity of the operation...
  57. ncbi Significance of multiple lymphatic basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy
    Jonathan B McHugh
    Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Ann Surg Oncol 13:1216-23. 2006
    ..In our experience, drainage to multiple lymphatic basins was not an independent risk factor for sentinel lymph node metastasis and has no independent prognostic significance...
  58. ncbi Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer
    Rachel M Layman
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109 0848, USA
    Clin Cancer Res 13:4092-7. 2007
    ..We evaluated whether TP protein expression is increased by docetaxel and correlates with pathologic complete response (pCR) in breast cancer patients...
  59. ncbi Surgical therapy of cutaneous melanoma
    Dan G Blazer
    Division of Surgical Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI, USA
    Semin Oncol 34:270-80. 2007
    ..This article will review the changes that have occurred leading to the current surgical approach to melanoma, the evidence behind these recommendations, and new questions that need to be addressed...
  60. ncbi Efficient tumour formation by single human melanoma cells
    Elsa Quintana
    Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine, and Center for Stem Cell Biology, University of Michigan, Ann Arbor, Michigan 48109 2216, USA
    Nature 456:593-8. 2008
    ..Modifications to xenotransplantation assays can therefore dramatically increase the detectable frequency of tumorigenic cells, demonstrating that they are common in some human cancers...
  61. ncbi Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
    Csaba Gajdos
    Department of Surgery, University of Michigan Health System, Ann Arbor, Michigan 48109 0932, USA
    Cancer 115:5752-60. 2009
    ..The authors examined the impact of SLN biopsy on prognosis and outcome in this patient population...
  62. ncbi Is there a role for sentinel lymph node biopsy in the management of sarcoma?
    Dan G Blazer
    Department of General Surgery, Division of Surgical Oncology, University of Michigan, 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Surg Oncol 12:201-6. 2003
    ..These include rhabdomyosarcoma, epithelioid sarcoma, clear cell sarcoma, synovial sarcoma, and vascular sarcomas. It is in these particular subtypes that there may be a benefit to SLN biopsy...
  63. ncbi Does the method of biopsy affect the incidence of sentinel lymph node metastases?
    Erika L Newman
    Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
    Breast J 12:53-7. 2006
    ..IHC should not be used routinely in the evaluation of the SLN and caution should be used when basing treatment decisions (completion axillary lymph node dissection or adjuvant therapy) on IHC-only detected micrometastases...
  64. ncbi Sentinel lymph node biopsy for breast cancer: how many nodes are enough?
    Shaheen Zakaria
    Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA
    J Surg Oncol 96:554-9. 2007
    ..Sentinel lymph node (SLN) biopsy using blue dye and radioisotope often results in the removal of multiple SLNs. We sought to determine whether there is a point where the surgeon can terminate the procedure without sacrificing accuracy...
  65. ncbi ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease
    Rainer Kuefer
    Department of Urology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109 0944, USA
    Neoplasia 8:319-29. 2006
    ..These results suggest that ADAM15 is generally overexpressed in adenocarcinoma and is highly associated with metastatic progression of prostate and breast cancers...
  66. ncbi Determinants of breast conservation rates: reasons for mastectomy at a comprehensive cancer center
    M Catherine Lee
    Division of Surgical Oncology, The Department of Surgery and the Biostatistics Core of the University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0932, USA
    Breast J 15:34-40. 2009
    ..Examining BCT rates alone as a measure of quality, therefore, is not an appropriate standard across institutions serving diverse populations...

Research Grants1

  1. Neoadjuvant Cytokine Immunotherapy by PLA Microspheres
    Michael Sabel; Fiscal Year: 2007
    ..I will pursue this area of investigation as a full-time faculty member, with full commitment from the Department of General Surgery and the Division of Surgical Oncology at the University of Michigan Medical Center. ..